CN101103978A - 小檗碱树脂复合物及其制备方法和含有其的药物组合物 - Google Patents
小檗碱树脂复合物及其制备方法和含有其的药物组合物 Download PDFInfo
- Publication number
- CN101103978A CN101103978A CNA2006100896965A CN200610089696A CN101103978A CN 101103978 A CN101103978 A CN 101103978A CN A2006100896965 A CNA2006100896965 A CN A2006100896965A CN 200610089696 A CN200610089696 A CN 200610089696A CN 101103978 A CN101103978 A CN 101103978A
- Authority
- CN
- China
- Prior art keywords
- berberine
- drug
- resin
- exchange resin
- ion exchange
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 title claims description 43
- 229940093265 berberine Drugs 0.000 title claims description 43
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 title claims description 43
- 238000002360 preparation method Methods 0.000 title description 42
- 239000000203 mixture Substances 0.000 title description 10
- 239000011342 resin composition Substances 0.000 title 1
- 229920005989 resin Polymers 0.000 claims abstract description 97
- 239000011347 resin Substances 0.000 claims abstract description 97
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims abstract description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000008367 deionised water Substances 0.000 claims abstract description 29
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 28
- 150000003836 berberines Chemical class 0.000 claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 19
- 238000005342 ion exchange Methods 0.000 claims abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 67
- 239000003456 ion exchange resin Substances 0.000 claims description 59
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 59
- 238000001035 drying Methods 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 9
- 239000003729 cation exchange resin Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 238000005341 cation exchange Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000007919 dispersible tablet Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 229920002253 Tannate Polymers 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 74
- 229940079593 drug Drugs 0.000 abstract description 48
- 235000019658 bitter taste Nutrition 0.000 abstract description 9
- 229920002125 Sokalan® Polymers 0.000 abstract description 4
- 210000001779 taste bud Anatomy 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000007788 liquid Substances 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000005303 weighing Methods 0.000 description 12
- 229920001429 chelating resin Polymers 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000011068 loading method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- -1 deionized water compound Chemical class 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002075 main ingredient Substances 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000010199 sorbic acid Nutrition 0.000 description 6
- 239000004334 sorbic acid Substances 0.000 description 6
- 229940075582 sorbic acid Drugs 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 230000009967 tasteless effect Effects 0.000 description 6
- 235000010493 xanthan gum Nutrition 0.000 description 6
- 239000000230 xanthan gum Substances 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- 229940082509 xanthan gum Drugs 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000811 xylitol Substances 0.000 description 5
- 235000010447 xylitol Nutrition 0.000 description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 5
- 229960002675 xylitol Drugs 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229940082484 carbomer-934 Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008359 toxicosis Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000106483 Anogeissus latifolia Species 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 244000179291 Mahonia aquifolium Species 0.000 description 1
- 235000002823 Mahonia aquifolium Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Chemical class 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000006502 papoula Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
时间(h) | 溶出度(%) | ||||||
1 | 2 | 3 | 4 | 5 | 6 | 平均值 | |
0.5 | 60.81 | 61.49 | 63.66 | 57.08 | 64.92 | 70.25 | 63.04 |
1 | 76.48 | 74.92 | 77.15 | 77.46 | 81.85 | 77.18 | 77.51 |
2 | 88.59 | 83.44 | 85.32 | 80.01 | 82.20 | 87.65 | 84.54 |
3 | 89.97 | 88.09 | 90.04 | 90.98 | 87.53 | 96.31 | 90.49 |
4 | 92.16 | 92.16 | 92.08 | 96.12 | 97.25 | 99.45 | 94.87 |
5 | 99.06 | 95.61 | 98.19 | 99.13 | 100.39 | 103.84 | 99.37 |
时间(h) | 溶出度(%) | ||||||
1 | 2 | 3 | 4 | 5 | 6 | 平均值 | |
0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
主辅料名称 | 处方量 |
盐酸小檗碱药物树脂复合物(比载药量为62.51%) | 13.0g |
黄原胶 | 1.5g |
木糖醇 | 300g |
1,2-丙二醇 | 60ml |
聚山梨酯-80 | 30mg |
尼泊金甲酯 | 1.2g |
尼泊金丙酯 | 0.3g |
山梨酸 | 1.0g |
香精 | 适量 |
水加至 | 1000ml |
开始高度 | 沉降最终高度 | 沉降体积比 | |
1 | 50.0 | 50.0 | 1.0 |
2 | 50.0 | 50.0 | 1.0 |
3 | 50.0 | 50.0 | 1.0 |
主辅料名称 | 处方量 |
盐酸小檗碱药物树脂复合物(比载药量为62.51%) | 13.0g |
糖浆 | 400ml |
黄原胶 | 1.8g |
1,2-丙二醇 | 80ml |
聚山梨酯-80 | 30mg |
尼泊金甲酯 | 1.2g |
尼泊金丙酯 | 0.3g |
山梨酸 | 1.0g |
香精 | 适量 |
水加至 | 1000ml |
开始高度 | 沉降最终高度 | 沉降体积比 | |
1 | 50.0 | 50.0 | 1.0 |
2 | 50.0 | 50.0 | 1.0 |
3 | 50.0 | 50.0 | 1.0 |
主辅料名称 | 处方量 |
盐酸小檗碱药物树脂复合物(比载药量为62.51%) | 13.0g |
木糖醇 | 80.0g |
微粉硅胶 | 1.0g |
微晶纤维素 | 10.0g |
香精 | 适量 |
甜味剂 | 适量 |
山梨酸 | 0.1g |
制成 | 100袋 |
开始高度 | 沉降最终高度 | 沉降体积比 | |
1 | 50.0 | 50.0 | 1.0 |
2 | 50.0 | 50.0 | 1.0 |
3 | 50.0 | 50.0 | 1.0 |
主辅料名称 | 处方量 |
盐酸小檗碱药物树脂复合物(比载药量为62.51%) | 13.0g |
低取代羟丙纤维素 | 8.0g |
交联羧甲淀粉钠 | 1.5g |
氢氧化铝 | 0.25g |
聚山梨酯80 | 0.2g |
3%PVPK30的40%乙醇液 | 适量 |
微粉硅胶 | 0.2g |
硬脂酸镁 | 1.0g |
制成 | 100片 |
主辅料名称 | 处方量 |
盐酸小檗碱药物树脂复合物(比载药量为62.51%) | 13.0g |
预胶化淀粉 | 5.0g |
乳糖 | 3.0g |
微晶纤维素 | 2.0g |
交联聚维酮 | 1.0g |
柠檬黄 | 适量 |
3%羟丙基甲基纤维素的70%乙醇液 | 适量 |
甜味剂 | 适量 |
微粉硅胶 | 0.5g |
制成 | 100片 |
主辅料名称 | 处方量 |
盐酸小檗碱药物树脂复合物(比载药量为62.51%) | 26.0g |
卡波姆934P | 0.3g |
制成 | 100粒 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100896965A CN101103978B (zh) | 2006-07-12 | 2006-07-12 | 小檗碱树脂复合物及其制备方法和含有其的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100896965A CN101103978B (zh) | 2006-07-12 | 2006-07-12 | 小檗碱树脂复合物及其制备方法和含有其的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101103978A true CN101103978A (zh) | 2008-01-16 |
CN101103978B CN101103978B (zh) | 2010-08-11 |
Family
ID=38998190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100896965A Active CN101103978B (zh) | 2006-07-12 | 2006-07-12 | 小檗碱树脂复合物及其制备方法和含有其的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101103978B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102151244A (zh) * | 2010-02-11 | 2011-08-17 | 普尔药物科技开发(深圳)有限公司 | 盐酸青藤碱药物树脂缓释混悬制剂及其制备方法 |
CN101716220B (zh) * | 2009-11-20 | 2012-07-04 | 杭州平和安康医药科技有限公司 | 掩蔽生物碱中药药物 |
CN105663040A (zh) * | 2016-01-18 | 2016-06-15 | 中国人民解放军第一七五医院 | 一种小檗碱纳米复合物及其制备方法 |
CN114315847A (zh) * | 2021-12-16 | 2022-04-12 | 科丝美诗(上海)检测科技有限公司 | 一种绿色环保的粉防己生物总碱的提取方法 |
-
2006
- 2006-07-12 CN CN2006100896965A patent/CN101103978B/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101716220B (zh) * | 2009-11-20 | 2012-07-04 | 杭州平和安康医药科技有限公司 | 掩蔽生物碱中药药物 |
CN102151244A (zh) * | 2010-02-11 | 2011-08-17 | 普尔药物科技开发(深圳)有限公司 | 盐酸青藤碱药物树脂缓释混悬制剂及其制备方法 |
CN105663040A (zh) * | 2016-01-18 | 2016-06-15 | 中国人民解放军第一七五医院 | 一种小檗碱纳米复合物及其制备方法 |
CN105663040B (zh) * | 2016-01-18 | 2018-08-10 | 中国人民解放军第一七五医院 | 一种小檗碱纳米复合物及其制备方法 |
CN114315847A (zh) * | 2021-12-16 | 2022-04-12 | 科丝美诗(上海)检测科技有限公司 | 一种绿色环保的粉防己生物总碱的提取方法 |
CN114315847B (zh) * | 2021-12-16 | 2024-05-03 | 科丝美诗(上海)检测科技有限公司 | 一种绿色环保的粉防己生物总碱的提取方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101103978B (zh) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1320926C (zh) | 银杏叶提取物组合物及其制备方法 | |
CN101596165A (zh) | 泮托拉唑钠肠溶微丸 | |
CN103893258B (zh) | 含有广金钱草总黄酮的口服固体制剂及其应用 | |
US11786506B2 (en) | Transmucosal psychoactive alkaloid composition and preparation thereof | |
CN101103978B (zh) | 小檗碱树脂复合物及其制备方法和含有其的药物组合物 | |
CN100488515C (zh) | 一种地红霉素肠溶微丸及制备方法 | |
CN106511260A (zh) | 一种盐酸小檗碱口服微丸干凝胶及其制备方法和应用 | |
CN103083557A (zh) | 具有降血压和降血脂作用的中药组合物 | |
CN107049981A (zh) | 一种速释氨磺必利药物组合物及其制备方法 | |
CN109157520B (zh) | 他达拉非片剂及其制备方法 | |
CN111568865A (zh) | 一种纳米晶颗粒及其制备方法 | |
CN102441019A (zh) | 一种中药菊花口含片 | |
CN101167770A (zh) | 一种改善口味的喉痛消炎中药制剂及其制备方法 | |
CN1857385B (zh) | 一种治疗颈椎病的药物组合物及其制备方法 | |
CN104086490A (zh) | 一种格列吡嗪化合物及含有该化合物的药物组合物及其制备方法 | |
CN101836981B (zh) | 复方缬沙坦苯磺酸氨氯地平药物组合物及其制备方法 | |
CN103070842B (zh) | 一种米格列醇缓释片的制备方法 | |
CN103127023A (zh) | 一种盐酸度洛西汀肠溶片及其制备方法 | |
CN103768071A (zh) | 一种治疗糖尿病的口服制剂 | |
CN103505421B (zh) | 一种盐酸度洛西汀的肠溶微丸制剂 | |
CN105902564A (zh) | 一种治疗高血压的药物组合物及制备方法 | |
CN110575443A (zh) | 一种多索茶碱缓释片及其制备方法 | |
CN101147806A (zh) | 小檗碱肠部控释微囊及其制备方法 | |
AU2021102578A4 (en) | Biopolymer nanosphere containing nadh, method of preparing the same and use thereof | |
CN108379237A (zh) | 一种治疗泌尿道感染的药物微囊制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING WEIHONG HECHUANG MEDICAL TECHNOLOGY CO., L Free format text: FORMER OWNER: LIANG WEI Effective date: 20100625 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100101 NO.15, DATUN ROAD, BEISHATAN, CHAOYANG DISTRICT, BEIJING TO: 100101 ROOM 501, 5TH FLOOR, BUILDING 35, NANSHATAN, CHAOYANG DISTRICT, BEIJING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100625 Address after: 100101, 501 floor, South Beach, building 35, room 5, Beijing, Chaoyang District Applicant after: Beijing Weihong Hechuang Medicine Technology Co., Ltd. Address before: 100101 Beijing city Chaoyang District North Beach Tatun Road No. 15 Applicant before: Liang Wei |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HANGZHOU AOPUKANG BIOTECHNOLOGY CO.,LTD. Free format text: FORMER OWNER: BEIJING WEIHONG HECHUANG MEDICINE TECHNOLOGY CO., LTD. Effective date: 20130115 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100101 CHAOYANG, BEIJING TO: 311200 HANGZHOU, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130115 Address after: Hangzhou City, Zhejiang province Xiaoshan District 311200 North Street 23 Yuan Jia know building 4 unit 1601 room Patentee after: Hangzhou spectrum Biotechnology Co., Ltd. Address before: 100101, 501 floor, South Beach, building 35, room 5, Beijing, Chaoyang District Patentee before: Beijing Weihong Hechuang Medicine Technology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING WEIHONG HECHUANG MEDICINE TECHNOLOGY CO., Free format text: FORMER OWNER: HANGZHOU AOPUKANG BIOTECHNOLOGY CO.,LTD. Effective date: 20130628 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 311200 HANGZHOU, ZHEJIANG PROVINCE TO: 100101 CHAOYANG, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130628 Address after: 100101, 501 floor, South Beach, building 35, room 5, Beijing, Chaoyang District Patentee after: Beijing Weihong Hechuang Medicine Technology Co., Ltd. Address before: Hangzhou City, Zhejiang province Xiaoshan District 311200 North Street 23 Yuan Jia know building 4 unit 1601 room Patentee before: Hangzhou spectrum Biotechnology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: ZHAOMING ZEKANG (BEIJING) BIOMEDICAL SCIENCE AND T Free format text: FORMER OWNER: BEIJING WEIHONG HECHUANG MEDICINE TECHNOLOGY CO., LTD. Effective date: 20150112 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100101 CHAOYANG, BEIJING TO: 100083 CHAOYANG, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150112 Address after: 100083, room 318, building B, Beijing Pioneer Building, No. 11 Xiang Bei Bei, Beijing, Chaoyang District Patentee after: Zhao Ming Zekang (Beijing) biological medicine science and Technology Co Ltd Address before: 100101, 501 floor, South Beach, building 35, room 5, Beijing, Chaoyang District Patentee before: Beijing Weihong Hechuang Medicine Technology Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20191106 Address after: 200120 building 6, No.92 and No.58, Zhangjiang Road, free trade Experimental Zone, Pudong New Area, Shanghai Patentee after: Shanghai Huiyong Pharmaceutical Research Co., Ltd. Address before: 100083, room 318, building B, Beijing Pioneer Building, No. 11 Xiang Bei Bei, Beijing, Chaoyang District Patentee before: Zhao Ming Zekang (Beijing) biological medicine science and Technology Co Ltd |
|
TR01 | Transfer of patent right |